All In Biotech

Drug Trial Radar · NCT06863662

Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm

Efficacy and Safety of the Fixed-Dose Combination of Etoricoxib / Tizanidine Versus Etoricoxib in the Treatment of Patients With Acute Low Back Pain Associated to Muscle Spasm

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

136

Actual

Start

Sep 18, 2024

Primary completion

Sep 26, 2025

Study completion Dec 1, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, longitudinal, multicenter, randomized, double-blind clinical trial. The aim of the study is to evaluate the efficacy and safety of a fixed-dose combination of etoricoxib and tizanidine compared to etoricoxib alone in patients with acute low back pain associated with muscle spasms.

Conditions

  • Acute Low-back Pain
  • Muscle Spasm; Back Pain

Interventions

  • Etoricoxib + Tizanidine fixed doseDrug

    One sachet with 120 mg / 4 mg, dissolved in 100 mL of water

  • Etoricoxib fixed doseDrug

    One sachet with 120 mg, dissolved in 100 mL of water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of the percentage change in pain intensity, as measured by the Visual Analog Scale (VAS), on Days 1, 3, 5, and 7 of follow-up relative to baseline, within each treatment group.Time frame: 7 days
  2. Number of participants reporting treatment-related adverse events, as documented in the patient diary.Time frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laboratorio Silanes, S.A. de C.V.

    Mexico City, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.